[go: up one dir, main page]

WO2011111070A3 - Nouvelle association injectable - Google Patents

Nouvelle association injectable Download PDF

Info

Publication number
WO2011111070A3
WO2011111070A3 PCT/IN2011/000159 IN2011000159W WO2011111070A3 WO 2011111070 A3 WO2011111070 A3 WO 2011111070A3 IN 2011000159 W IN2011000159 W IN 2011000159W WO 2011111070 A3 WO2011111070 A3 WO 2011111070A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
novel injectable
injectable combination
formulation
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000159
Other languages
English (en)
Other versions
WO2011111070A2 (fr
Inventor
Dharmesh Mahendrabhai Shah
Guruprasad Ramchandra Wader
Trushit Pramodray Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BDR PHARMACEUTICALS INTERNATIONAL PVT Ltd
Original Assignee
BDR PHARMACEUTICALS INTERNATIONAL PVT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BDR PHARMACEUTICALS INTERNATIONAL PVT Ltd filed Critical BDR PHARMACEUTICALS INTERNATIONAL PVT Ltd
Publication of WO2011111070A2 publication Critical patent/WO2011111070A2/fr
Publication of WO2011111070A3 publication Critical patent/WO2011111070A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet une formulation injectable stable comprenant une association de Citicoline et d'Edaravone avec un dérivé de Cyclodextrine, utile pour le traitement de troubles du système nerveux central et d'accidents vasculaires cérébraux ischémiques et concerne en outre un procédé de préparation de ladite formulation.
PCT/IN2011/000159 2010-03-09 2011-03-09 Nouvelle association injectable Ceased WO2011111070A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2592MU2009 2010-03-09
IN2592/MUM/2009 2010-03-09

Publications (2)

Publication Number Publication Date
WO2011111070A2 WO2011111070A2 (fr) 2011-09-15
WO2011111070A3 true WO2011111070A3 (fr) 2011-12-22

Family

ID=44563942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000159 Ceased WO2011111070A2 (fr) 2010-03-09 2011-03-09 Nouvelle association injectable

Country Status (1)

Country Link
WO (1) WO2011111070A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006550A (zh) * 2012-12-11 2013-04-03 哈药集团三精制药股份有限公司 一种胞磷胆碱钠注射液及其制备方法
CN103351342B (zh) * 2013-07-03 2015-08-05 浙江中医药大学 一种依达拉奉药物共晶及其制备方法
CN105012230B (zh) * 2014-04-30 2018-01-16 长春海悦药业股份有限公司 一种依达拉奉的药物组合物
CN104490771A (zh) * 2014-12-19 2015-04-08 成都天台山制药有限公司 胞磷胆碱钠注射液药物组合物和制法
CN110090225B (zh) * 2019-04-19 2021-07-16 济南康和医药科技有限公司 一种依达拉奉氯化钠注射液及其制备方法
CN111840220B (zh) * 2020-08-19 2022-09-30 开封康诺药业有限公司 一种胞磷胆碱钠注射液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142906A1 (en) * 2001-09-24 2004-07-22 Yanming Wang Conpositions and method to prevent and treat brain and spinal cord injuries
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US20080312226A1 (en) * 2004-11-18 2008-12-18 Takeda Pharmaceutical Company Limited Amide Compound
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US20040142906A1 (en) * 2001-09-24 2004-07-22 Yanming Wang Conpositions and method to prevent and treat brain and spinal cord injuries
US20080312226A1 (en) * 2004-11-18 2008-12-18 Takeda Pharmaceutical Company Limited Amide Compound
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration

Also Published As

Publication number Publication date
WO2011111070A2 (fr) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2012156998A3 (fr) Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron
WO2015085318A3 (fr) Vaccins adaptatifs ciblés
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
WO2012076466A3 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
WO2011138281A3 (fr) Procédé de production de dithiine-tétracarboxy-diimides
WO2012061607A3 (fr) Compositions comprenant des nanostructures fonctionnalisées à base de carbone et procédés associés
PL2994229T3 (pl) Sposób wytwarzania 1,3-butadienu
WO2015110897A3 (fr) Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables
AP2014007436A0 (en) A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
WO2011111070A3 (fr) Nouvelle association injectable
WO2010102778A3 (fr) 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
WO2014125506A3 (fr) Procédé de préparation d'ivacaftor et de ses intermédiaires
WO2014036502A8 (fr) Composés de tétracyclines
WO2015037016A3 (fr) Procédé amélioré de préparation de ticagrelor et d'intermédiaires de celui-ci
WO2015052568A3 (fr) Formes solides de curcumine et de dérivés de curcumine
HK1213151A1 (zh) 叶黄素组合物及使用方法
PL2797863T3 (pl) Sposób wytwarzania 1,3-butadienu
WO2011136513A3 (fr) Composition de greffe osseuse ou d'obturation osseuse comprenant un dérivé d'acide dihydroxybenzoïque
HK1212978A1 (zh) 芥子酸的新型衍生物
BR112012027144A2 (pt) agente espessante derivado de tomate, processo para preparar um agente espessante derivado de tomate,, método para preparação de um produto alimentícios e produto de ketchup de tomate obtenível pelo processo
WO2012018791A3 (fr) Préparation de chlorhydrate de prasugrel
WO2010134048A3 (fr) Solutions de rétinoïdes topiques
WO2013113037A8 (fr) Procédés améliorés de production d'éthylènes disubstitués en 1,1
WO2014195977A3 (fr) Nouveaux polymorphes de vismodegib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11752949

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11752949

Country of ref document: EP

Kind code of ref document: A2